

Pharmacy Formulary Updates for September 2019

To offer a pharmacy benefit that is clinically appropriate and cost effective, we constantly review how we cover prescription medications. Periodic adjustments are made to meet these goals. With the exception of new-to-market medications, the changes below are reflected in our online Preferred Drug List.

The following is a list of drugs that changed formulary status in September 2019:

Drug Name	Tufts Health Public Plan Formulary
	Tufts Health Direct Formulary
Skyrizi	T2;PA;QL;SP
Nucala auto-injector, prefilled syringe	T2;PA;SP
Ruzurgi	T2;PA
bosentan tablets	T1;PA;SP
sildenafil citrate oral suspension	T1;PA;SP
icatibant	T2;PA;QL;SP
Parsabiv	MB
Inbrija	T3;PA
estradiol vaginal tablets	T1
Evenity	MB;PA
Aemcolo	T3;QL
Motegrity	NC;QL
Qmiiz ODT	NC
Adhansia XR	NC;QL
Evekeo ODT	NC
Ezallor	NC;QL
Slynd	T3
Thiola EC	T3
loteprednol suspension	T2
febuxostat	T2;STPA
fentanyl citrate buccal tablets	T2;QL
doxylamine-pyridoxine	NC
ramelteon	T2;STPA;QL
pregabalin	T1;STPA

Key:

MB: Medical Benefit

NC: Not covered

NTM: New-to-market

PA: Prior Authorization

QL: Quantity Limitation

SP: Specialty Pharmacy - provided
through CVS/specialty

ST: Step Therapy